Skip to content

Dexcom CONNECT Study on CGM Benefits for Type 2 Diabetes

The CONNECT randomized controlled trial showed that the use of Dexcom G7 leads to significant reductions in A1C levels and improvements in glucose control in individuals with Type 2 diabetes not using insulin, compared to those only self-monitoring their blood glucose.

SAN DIEGO–(BUSINESS WIRE)–DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significant reduction in A1C and improvement in glucose control among people with Type 2 diabetes not using insulin compared with a routine care control group using self-monitoring of blood glucose.1 Researchers presented these results today as an oral presentation at the 2026 Scientific Sessions of